Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.

Clinical otolaryngology : official journal of ENT-UK ; official journal of Netherlands Society for Oto-Rhino-Laryngology & Cervico-Facial Surgery - 1 Feb 2015

Sheikh S I, Long F R, McCoy K S, Johnson T, Ryan-Wenger N A, Hayes D

Abstract excerpt

BACKGROUND: Most patients with Cystic fibrosis (CF) have chronic sinus disease which may require multiple sinus surgeries and antibiotic courses. Ivacaftor can improve lung function, lower sweat chloride levels and improve weight by targeting the primary defect, a faulty gene and its protein product, cystic fibrosis transmembrane conductance regulator (CFTR) in patients with the G551D mutation. Its role in...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminophenols
Share to Cohort Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cystic Fibrosis

Share to Cystic Fibrosis Transmembrane Conductance Regulator

Share to Quinolones

Share to Tomography, X-Ray Computed

Share to Treatment Outcome

Share to Young Adult

Source

Identifiers

PMID: 25145599
DOI: 10.1111/coa.12310

Genes

CFTR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Ivacaftor improves appearance of sinus disease on computerised tomography in cystic fibrosis patients with G551D mutation.PMID 25145599Read ↗

Computed tomography correlates with improvement with ivacaftor in cystic fibrosis patients with G551D mutation.Semantic proximity Read ↗

Development, clinical utility, and place of ivacaftor in the treatment of cystic fibrosis.Semantic proximity Read ↗

Ivacaftor treatment in patients with cystic fibrosis and the G551D-CFTR mutation.Semantic proximity Read ↗

Ivacaftor treatment of cystic fibrosis patients with the G551D mutation: a review of the evidence.Semantic proximity Read ↗

VOCAL: An observational study of ivacaftor for people with cystic fibrosis and selected non-G551D-CFTR gating mutations.Semantic proximity Read ↗

Efficacy and safety of ivacaftor in patients aged 6 to 11 years with cystic fibrosis with a G551D mutation.Semantic proximity Read ↗

Effect of ivacaftor in patients with advanced cystic fibrosis and a G551D-CFTR mutation: Safety and efficacy in an expanded access program in the United States.Semantic proximity Read ↗

Ivacaftor and sinonasal pathology in a cystic fibrosis patient with genotype deltaF508/S1215N.Semantic proximity Read ↗

Acute administration of ivacaftor to people with cystic fibrosis and a G551D-CFTR mutation reveals smooth muscle abnormalitiesSemantic proximity Read ↗

Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.Semantic proximity Read ↗

The impact of ivacaftor on sinonasal pathology in S1251N-mediated cystic fibrosis patients.Semantic proximity Read ↗

Ivacaftor: Five-year outcomes in the West of Scotland cystic fibrosis population.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.